Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Cet article présente une mise à jour des recommandations de l'"American Society of Clinical Oncology" sur la prise en charge initiale d'un cancer de la prostate récidivant, métastatique ou de stade avancé
In 2021, ASCO updated a guideline on the initial management of noncastrate recurrent, advanced, or metastatic prostate cancer.1 Several recent developments prompted this focused update. First, at the time of the 2021 update, the results from the ARASENS2 trial were not yet available and darolutamide was not yet US Food and Drug Administration–approved for patients with noncastrate de novo metastatic prostate cancer. However, on August 5, 2022, darolutamide, in combination with docetaxel and androgen-deprivation therapy (ADT; triplet therapy), was US Food and Drug Administration–approved for these patients based on the results of the ARASENS trial2 and is one of several reasons an update was deemed necessary.
Journal of Clinical Oncology , résumé, 2022